ArticleFrontiers in oncology2020

Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma.

Weiwei Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.